Answers are grounded in this paper and cite their sources.
Transdermal drug delivery systems (TDDS) are used to deliver an active pharmaceutical ingredient through the skin, typically to deliver a systemic dose whilst avoiding degradation in the GIT. TDDS performance is limited by the stratum corneum, drug physicochemical properties, formulation thermodynamics, application conditions and patient variability. This review considers how the skin anatomy works, conventional TDDS (reservoir, matrix and drug-in-adhesive), formulation ingredients, passive and active skin permeation enhancement, microneedles, nanocarriers, testing methods, therapeutic applications, challenges in manufacture, safety and regulation. Conventional TDDS have demonstrated the benefits of controlled delivery to deliver a limited number of high potency, low dose molecules. Newer TDDS are being developed to increase the variety of molecules that can be delivered, improve patient compliance or allow responsive and personalized dosing. However, enhancing permeation does not automatically mean a clinical benefit will be achieved. There needs to be a reliable, controllable, well tolerated and manufacturable delivery system. In vitro release, ex vivo skin permeation, skin integrity, adhesion, stability and well-designed clinical pharmacokinetic studies should be performed. Key issues to overcome in this field are having standardised methodologies, reliable models using human skin, scalable manufacturing, long term safety, clear quality attributes and realistic claims. This narrative review highlights the importance of interpreting the evidence and differentiates between technologies currently on the market and those under investigation.
No takes yet. Share an insight, caveat, or question.
Vishe et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: